The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia

[1]  Sean D Sullivan,et al.  Methods to assess intended effects of drug treatment in observational studies are reviewed. , 2004, Journal of clinical epidemiology.

[2]  A. Anzueto,et al.  Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. , 2004, The American journal of medicine.

[3]  D. Snydman,et al.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. , 2004, American journal of respiratory and critical care medicine.

[4]  M. Fine,et al.  Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Makuc,et al.  Health, United States, 2003; with chartbook on trends in the health of Americans , 2003 .

[6]  P. Gross,et al.  Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. , 2003, Chest.

[7]  Á. Soriano,et al.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Parnham,et al.  Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. , 2002, European journal of pharmacology.

[9]  M. Fine,et al.  Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. , 2002, Archives of internal medicine.

[10]  J. Rello,et al.  Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia , 2002, Intensive Care Medicine.

[11]  D. Battleman,et al.  Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. , 2002, Archives of internal medicine.

[12]  W. Lim,et al.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults , 2001, Thorax.

[13]  D. Malone,et al.  Adherence to ATS Guidelines for Hospitalized Patients with Community-Acquired Pneumonia , 2001, The Annals of pharmacotherapy.

[14]  R. Wunderink,et al.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. , 2001, Archives of internal medicine.

[15]  M. Niederman,et al.  Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997. , 2001, Chest.

[16]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[17]  R. Chaisson.  Guidelines for the management of community-acquired pneumonia , 2000, The American journal of managed care.

[18]  L. Mandell,et al.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. , 2000, Canadian respiratory journal.

[19]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  L. Mandell,et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Burgess,et al.  Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. , 2000, Clinical therapeutics.

[22]  J. Nicolás,et al.  Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls , 2000, Thorax.

[23]  L. Mandell,et al.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. , 2000, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[24]  F. D’Acquisto,et al.  Anti-inflammatory activity of macrolide antibiotics. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  M. Fine,et al.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. , 1999, Archives of internal medicine.

[26]  J E Stahl,et al.  Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. , 1999, Archives of internal medicine.

[27]  M. Labro.  Anti-inflammatory activity of macrolides: a new therapeutic potential? , 1998, The Journal of antimicrobial chemotherapy.

[28]  Guidelines for the initial Management of Adults with Community-acquired Pneumoma : Diagnosis , Assessment of Severity ; and initial Antimicrobial fieraky , 1998 .

[29]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[30]  P. Black.  Anti-inflammatory effects of macrolide antibiotics. , 1997, The European respiratory journal.

[31]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[32]  A. Puren,et al.  Patterns of cytokine expression in community-acquired pneumonia. , 1995, Chest.

[33]  M. Fine,et al.  Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. , 1995, Medical care.

[34]  A. Ortqvist,et al.  Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. , 1995, Scandinavian journal of infectious diseases.

[35]  L. Bianchi,et al.  Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy. , 1995, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[36]  M. Fine,et al.  Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. , 1994, Seminars in respiratory infections.

[37]  I. Cree,et al.  Phagocyte function and cytokine production in community acquired pneumonia. , 1994, Thorax.

[38]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[39]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[40]  T. van der Poll,et al.  Effects on leukocytes after injection of tumor necrosis factor into healthy humans. , 1992, Blood.

[41]  F. Taylor,et al.  Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. , 1991, Circulatory shock.

[42]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[43]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[44]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.